|PRRUF -- USA Stock|| |
USD 0.02 0.00 0.00%
Dr. Sharron Gargosky is Chief Technical Officer of Prima Biomed Ltd. and was with Prima BioMed since August 2010. Dr. Gargosky has over 19 years experience in the biotechnology and pharmaceutical industries and has worked in senior positions in organizations that have successfully received FDA approval for orphan drugs. She is responsible for managing the clinical team working on the CVac immunotherapy cancer vaccine. Prior to joining Prima BioMed Dr. Gargosky was a member of ILMU consulting LLC where she provided project management and operational expertise on pharmaceutical drug and biologic development from early research to Phase IV Trials and the FDA approval process. Dr. Gargosky has also previously held the positions of Chief Scientific Officer at Pulse Health LLC in Portland in the USA and Chief Scientific Officer and Senior Vice President of Corporationrationrate Development at Hyperion Therapeutics Inc. in San Francisco. At Ucyclyd Pharma she managed the approval of orphan drug products and the development of the NCE and within Medics Pharmaceuticals the successful BLA submission and approval for Reloxin. As Vice President of Business Development for Diagnostic System Laboratories she was responsible for business expansion through evaluation and implementation of new growth opportunities and patent portfolio management
Age: 50 Executive Since 2012 Ph.D
61 2 8315 7003 http://www.primabiomed.com.au
Gargosky has a Postdoctoral Fellowship in Pediatric Endocrinology from Stanford University in California, a Ph.D in biochemistry from University of Adelaide in Australia, First Class Honors in Biochemistry from University of Adelaide, and a BS, Biochemistry, Microbiology, Immunology & Virology from University of Adelaide.